(Q54191774)

26 May 2018

title

Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3. (English)

1 reference

26 May 2018

secondary hyperparathyroidism

1 reference

1 reference

L Djukanović

1

1 reference

26 May 2018

S Pejanović

series ordinal

2

1 reference

26 May 2018

Z Dragojlović

series ordinal

3

1 reference

26 May 2018

M Stosović

series ordinal

4

1 reference

26 May 2018

publication date

1 November 1994

1 reference

26 May 2018

published in

Renal Failure

1 reference

26 May 2018

volume

16

1 reference

26 May 2018

issue

6

1 reference

26 May 2018

page(s)

715-723

1 reference

26 May 2018

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08860229409044901

Treatment of refractory hyperparathyroidism in patients on hemodialysis by intermittent oral administration of 1,25(OH)2vitamin D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860229409044901

Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860229409044901

Parathyroid gland function in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860229409044901

Oral administration of 24,25(OH)2D3 suppresses the serum parathyroid hormone levels of dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860229409044901

10.3109/08860229409044901

21 January 2018

Identifiers

DOI

1 reference

26 May 2018

1 reference

26 May 2018